SWK Holdings Corporation Stock

Equities

SWKH

US78501P2039

Corporate Financial Services

Market Closed - Nasdaq 04:00:00 2024-04-24 pm EDT 5-day change 1st Jan Change
17.01 USD -1.51% Intraday chart for SWK Holdings Corporation -1.85% -2.97%
Sales 2024 * 38.9M Sales 2025 * 41.3M Capitalization 213M
Net income 2024 * 23M Net income 2025 * 14M EV / Sales 2024 * 5.46 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 5.15 x
P/E ratio 2024 *
9.19 x
P/E ratio 2025 *
14.7 x
Employees 23
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.07%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.51%
1 week-1.85%
Current month-2.35%
1 month-3.08%
3 months-0.23%
6 months+6.71%
Current year-2.97%
More quotes
1 week
16.78
Extreme 16.78
17.74
1 month
16.70
Extreme 16.7
18.30
Current year
15.92
Extreme 15.92
18.49
1 year
15.26
Extreme 15.26
18.75
3 years
15.26
Extreme 15.26
20.49
5 years
0.00
Extreme 0
20.49
10 years
0.00
Extreme 0
45.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 43 15-07-31
Comptroller/Controller/Auditor - 23-06-30
Corporate Officer/Principal - 22-01-31
Members of the board TitleAgeSince
Chairman 63 22-02-08
Director/Board Member 61 22-02-14
Director/Board Member 36 21-05-16
More insiders
Date Price Change Volume
24-04-24 17.01 -1.51% 3,294
24-04-23 17.27 +0.12% 7,090
24-04-22 17.25 -2.49% 8,117
24-04-19 17.69 +2.02% 7,693
24-04-18 17.34 +0.06% 3,737

Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT

More quotes
SWK Holdings Corporation is engaged in specialty finance and asset management business. The Company’s segments include Finance Receivables and Pharmaceutical Development. Finance Receivables segment is a healthcare capital provider, which offers customized financing solutions to a range of life science companies, institutions, and inventors. This segment is primarily focused on monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Its Pharmaceutical Development segment operates through its subsidiary Enteris BioPharma, Inc. (Enteris). Enteris is a clinical development and manufacturing organization providing development services to pharmaceutical partners as well as innovative formulation solutions built around its oral drug delivery technologies, the Peptelligence platform.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
17.01 USD
Average target price
24 USD
Spread / Average Target
+41.09%
Consensus